Hormone replacement therapy has been helping women manage menopause symptoms for decades, yet its long-term effects on brain health remain a subject of intense study. A large new analysis from the UK Biobank suggests that hormone therapy for menopause might be linked to a lower dementia risk for some women, particularly depending on when treatment begins and the type of menopause they experience. As researchers continue to explore the complex relationship between menopause, estrogen, and brain health, this study adds another important piece to the puzzle surrounding hormone therapy and dementia risk.

The research, published in 2026 in the journal Alzheimer’s & Dementia, followed 183,450 postmenopausal women from the UK Biobank for an average of 13 years, amounting to roughly 2.43 million person-years of observation. Over that time, 3,948 cases of dementia were diagnosed. When the researchers compared women who had used hormone replacement therapy for at least one year with those who had never used it, they found that HRT users were about 10% less likely to develop all-cause dementia and 16% less likely to develop Alzheimer’s disease. At first glance, those numbers might sound straightforward, but the story becomes much more nuanced once individual factors are taken into account.

One of the clearest signals in the data emerged among women who had undergone surgical menopause. Unlike natural menopause, which involves a gradual decline in estrogen over several years, surgical menopause can cause estrogen levels to fall sharply in a very short period of time, especially when both ovaries are removed. This abrupt change appears to create a distinct vulnerability in the brain. In the UK Biobank study, women with surgical menopause who used HRT had a 26% lower risk of developing any form of dementia compared with surgical menopause patients who did not use hormone therapy. This suggests that when menopause is sudden, replacing lost hormones may have a particularly meaningful impact on long-term cognitive health.

The research also highlighted the role of lifetime estrogen exposure. Women who had fewer total years of natural estrogen, such as those who started their periods later in life or experienced menopause earlier than average, seemed to benefit more from hormone therapy. In this group, HRT use was associated with a 16% lower risk of all-cause dementia. In contrast, women whose reproductive years involved more abundant estrogen exposure, followed by a gradual and natural decline, may have had less to gain in terms of dementia risk reduction. These findings support the idea that a woman’s hormonal history influences how her brain responds to hormone therapy later on.

Timing, however, appeared to be the most critical factor. The study found that starting hormone therapy between the ages of 46 and 56 was associated with the 10% reduction in dementia risk, while that association was not seen in women who began HRT after age 56. This pattern is consistent with what scientists call the “critical window” hypothesis. According to this concept, the brain may remain sensitive to estrogen for only a finite period after menopause. Within this window, estrogen replacement may help support brain metabolism and preserve healthier patterns of aging. Once that window closes and estrogen receptors in the brain downregulate, adding hormones later might bring less benefit and, in some circumstances, could even be unfavorable.

Earlier research contributed to this idea, including the Women’s Health Initiative Memory Study (WHIMS), published in JAMA, which reported that combined estrogen plus progestin therapy increased the risk of probable dementia in women who were 65 and older at the time they entered the trial. Those participants were already well beyond the typical age of menopause. The contrast between WHIMS and more recent observational studies has reinforced the importance of asking not only whether a woman uses hormone therapy, but also when she starts and what her overall hormonal trajectory has been.

Genetics added another layer to the UK Biobank findings. The APOE4 gene variant is the strongest known genetic risk factor for Alzheimer’s disease and appears to carry a greater impact in women than in men. Around a quarter of people carry one copy of APOE4, while a smaller percentage carry two. In this study, women with the APOE4 variant who used hormone therapy had a 13% lower risk of dementia compared with APOE4 carriers who did not use HRT. That effect size is modest and again reflects an association rather than proof of protection, but it raises the possibility that genetic makeup may shape who stands to gain the most from timely hormone therapy. Some researchers are beginning to explore whether genetic screening could one day help guide personalized decisions about when to start or avoid HRT.

It is essential to emphasize that the UK Biobank study was observational. Women were not randomly assigned to hormone therapy or a placebo. Instead, the researchers observed what happened to women who chose to use HRT compared with those who did not. This means that other differences between the two groups, such as general health, lifestyle, socioeconomic status, access to medical care, or underlying risk factors, could have influenced the dementia outcomes. The investigators tried to adjust for many of these variables, including age, health conditions, and socioeconomic background, yet they acknowledged that “residual confounding” is still very possible. In other words, association does not prove causation.

Even with that limitation, this work has helped reshape how clinicians and regulators think about hormone therapy for menopause. In late 2025, the U.S. Food and Drug Administration requested that black-box warnings be removed from hormone therapy products to better align labeling with the current understanding of HRT’s benefits and risks. Those prominent warnings were originally influenced heavily by the WHIMS findings in older women. As newer evidence accumulates, including data from studies like the UK Biobank and mechanistic research in Physiological Reviews that describes how estrogen supports memory-related brain regions such as the prefrontal cortex and hippocampus, the conversation around hormone therapy has shifted toward a more individualized and time-sensitive approach.

For women, the practical takeaway is not that hormone therapy should be started purely as a dementia prevention strategy. Current guidance still frames HRT primarily as a way to manage bothersome menopausal symptoms such as hot flashes, night sweats, and sleep disruption. The new findings do not overturn that principle. What they do suggest is that when a woman is already considering hormone therapy, it may be helpful for her and her clinician to factor in age, type of menopause, lifetime estrogen exposure, and genetics if known. For a woman in her late 40s or early 50s with significant menopause symptoms, the possibility of modest long-term cognitive benefits may be part of a broader, personalized risk-benefit discussion. For someone well past age 56 who is not already on HRT, the evidence does not indicate the same potential advantage, and in some cases may support a more cautious stance.

Professor Anne-Marie Minihane of the University of East Anglia’s Norwich Medical School, who led the research, noted that while HRT has long been prescribed mainly to relieve symptoms like hot flushes and night sweats, this work suggests it may also play a role in long-term cognitive health for some women. I found this detail striking, because it underlines how the same therapy can have different implications depending on who is taking it and when they begin. Rather than asking whether hormone therapy is simply “good” or “bad,” this study encourages a more nuanced question: which women, at which time, and under what circumstances might see brain health benefits.

Ultimately, decisions about hormone therapy for menopause remain deeply personal. Anyone thinking about starting, continuing, or stopping HRT should have a thorough conversation with a qualified healthcare provider who can weigh symptom relief, cardiovascular and cancer risks, bone health, and now potentially cognitive outcomes. The UK Biobank study does not provide all the answers, but it adds valuable context to those discussions and highlights the increasing importance of tailoring menopause care to each individual’s biology and life history. This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek personalized guidance from a healthcare professional before making decisions about hormone therapy or any medication. Read more at https://theheartysoul.com/hormone-therapy-dementia-risk/